Neuronetics, Inc. - Common Stock (STIM)

Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release, Q2 earnings

Neuronetics (NASDAQ:STIM) reported second-quarter 2026 revenue growth, a sharply narrower net loss and positive adjusted EBITDA as its Greenbrook clinic business expanded and the company introduced additional commercial purchasing options for its NeuroStar transcranial magnetic stimulation, or TMS,

Neuronetics (STIM) Q1 2026 Earnings Transcript

Neuronetics (STIM) Q4 2025 Earnings Transcript

The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Neuronetics (STIM) Q3 2025 results: revenue miss sparks a 22% stock drop despite a narrower-than-expected EPS loss.

Neuronetics (STIM) reported mixed Q2 2025 results, beating revenue estimates but posting a wider-than-expected loss, causing a 9% pre-market drop. Greenbrook clinics hit record revenue.